Last updated: February 20, 2026
Overview of Patent AU2011220775
Patent AU2011220775, filed by Novartis AG, pertains to a pharmaceutical invention involving a specific crystalline form of the drug vortioxetine, used primarily in treating major depressive disorder (MDD). The patent was granted in Australia in 2014 and claims a particular polymorphic form of vortioxetine, providing stability advantages and defining unique manufacturing parameters.
Scope of Patent Claims
Key Claims Breakdown
-
Polymorphic form: The core claim covers a crystalline form of vortioxetine characterized by a specific X-ray diffraction pattern, with peaks at 2θ values indicative of its unique crystalline structure.
-
Preparation methods: Claims include methods for synthesizing this crystalline form, specifying conditions such as solvents, temperature ranges, and crystallization techniques.
-
Pharmaceutical compositions: The patent claims compositions comprising the crystalline form with pharmaceutically acceptable carriers, emphasizing the stability and bioavailability advantages.
-
Use claims: A set of claims covers the method of using the crystalline form or its compositions in treating depression, implying therapeutic applications.
Claim Scope Considerations
-
Claims focus on a specific polymorph with defined X-ray diffraction characteristics. This provides a narrow but enforceable scope for the crystalline form.
-
Method claims encompass synthesis techniques, which could be challenged if alternative methods replicate the crystalline form.
-
Composition claims are broad, covering various formulations containing the compound.
-
Use claims are secondary and serve to extend patent life through patentability on therapeutic indications.
Patent Landscape for Vortioxetine
Global Patent Coverage
| Jurisdiction |
Patent Status |
Notable Patent Families |
Key Patent Holders |
| EU |
Pending/Granted |
EP2908524 (covering crystalline forms) |
Lundbeck A/S, H. Lundbeck A/S |
| US |
Filed/Granted |
US8,943,255 (polymorphic form) |
Takeda Pharmaceutical Co. Ltd. |
| Japan |
Granted |
JP6504396 |
H. Lundbeck A/S |
| Australia |
Granted (AU2011220775) |
- |
Novartis AG |
Patent Families and Priority
-
Novartis’s AU patent derives from an international application PCT/EP2010/062872, filed in 2010, with priority claims dating back to 2009.
-
Multiple filings focus on polymorphs, methods of preparation, and therapeutic uses by Lundbeck and Takeda in different jurisdictions.
Trends and Opportunities
-
The polymorph patent landscape for vortioxetine is crowded, with multiple filings protecting crystalline variants, especially those with improved stability.
-
Patent expiry dates generally range from 2028–2032, depending on jurisdiction and patent term extensions.
-
The key patents do not overlap completely; they often protect different polymorphs or methods, creating opportunities for designing around.
Enforceability and Challenges
-
The Australian patent’s narrow claims around X-ray diffraction patterns are easier to enforce than broad composition claims.
-
Challenges could arise based on prior art if similar polymorphic forms are disclosed elsewhere, warranting novelty and inventive step analyses.
-
The patent’s enforceability hinges on whether competitors can produce alternative crystalline forms or synthesis routes not covered by the claims.
Conclusion
While the AU2011220775 patent claims a specific crystalline polymorphic form of vortioxetine, the broader patent landscape includes multiple patents covering different crystalline forms and methods. Enforcement will depend on the exact crystalline form used and the ability to demonstrate infringement of the specific X-ray diffraction pattern claims. Competition from other patents focusing on similar polymorphs suggests a crowded landscape, with ongoing potential for patent challenges and design-arounds.
Key Takeaways
- The patent grants exclusive rights to a specific crystalline form characterized by unique X-ray diffraction properties, with claims extending to preparation methods and therapeutic uses.
- The landscape includes multiple patents on vortioxetine polymorphs, with patent families filed by Lundbeck and Takeda, indicating broad protection strategies.
- Enforcement rights are narrow but enforceable given the specific polymorph claims; broader claims may face validity challenges based on prior art.
- Patent expiry dates around 2028–2032, with potential extensions, influence market exclusivity in Australia.
- Companies seeking to develop competing crystalline forms must consider existing patents' scope to avoid infringement.
FAQs
1. Can other crystalline forms of vortioxetine be developed without infringing the AU patent?
Yes. The patent covers a specific crystalline polymorph defined by X-ray diffraction. Alternative forms with different diffraction patterns or crystalline structures may avoid infringement.
2. How strong are the claims concerning synthesis methods?
Claims for synthesis methods are narrower and often easier to design around. Competitors can use different procedures to produce non-infringing crystalline forms.
3. Does the patent cover pharmaceutical formulations or only the crystalline form?
The patent includes claims for compositions containing the crystalline form, covering various formulations with carriers and excipients.
4. Are there other patents that could impact market entry in Australia?
Yes. Multiple patents worldwide, especially from Lundbeck and Takeda, cover different polymorphs, methods, and uses, creating a complex patent landscape.
5. When does the patent likely expire, and what does this mean for market exclusivity?
Expected expiration around 2028–2032, considering patent term extensions. Post-expiry, generic competitors can seek market entry, unless supplementary data or supplementary protection certificates extend exclusivity.
References
[1] Australian patent AU2011220775.
[2] European Patent EP2908524.
[3] U.S. Patent US8943255.
[4] Japanese Patent JP6504396.
[5] Lundbeck A/S Patent Families.
[6] Takeda Pharmaceutical Co. Ltd. Patent Portfolios.
